The Research Department at Whitman-Walker conducts cutting-edge scientific research on HIV/STD treatment and prevention.  We strive to improve the lives of People with HIV and to promote the health and well-being of diverse urban communities.  Through partnerships with academic institutions, local and federal governments and a broad network of key stakeholders, we evaluate methods for curbing the spread of HIV and STDs, study the latest developments in Antiretroviral Therapy and help translate scientific findings to community practice.  

Primary goals for research at WWH:

  • Use scientific methods to test and develop effective forms of   HIV/STD prevention, detection and treatment programs
  • Build on our expertise in the area of LGBT health care to contribute to larger efforts in making affirming care accessible to every LGBT community
  • Establish the value and advantages of integrating sound research and primary care in community settings
  • Recognize that medical,  psychosocial, and structural interventions are key in achieving healthy populations
  • Evaluate novel programs and treatments that help us better respond to ever-changing problems in our community

The Research department is located in the Elizabeth Taylor Medical Center, at 1701 14th St., NW. For more information, call 202.745.6172.

New Treatments for Hepatitis C
WWH is starting several studies that evaluate cutting edge treatments for Hepatitis C.  Our current projects study once-daily treatments and treatments that are effective without the use of Peg-Interferon.  These studies will help create simplified regimens for people with Hepatitis C.   

Once-Daily Regimens for HIV Treatment
Working with pharmaceutical companies to test new treatments gives our clients access to the latest medications and easiest to take regimens in development.  We currently have novel, once-daily regimens available for patients who have never taken HIV medications.

Pre-Exposure Prophylaxis (PrEP)
Whitman-Walker Health is conducting a study on pre-exposure prophylaxis (PrEP), the latest FDA approved tool available to prevent HIV infection. Several studies have shown that PrEP can reduce the risk of becoming HIV-infected when taken as part of a package of prevention services. This project will provide important information about how PrEP can be used as an HIV prevention method in our community. The project is no longer recruiting.

Whitman-Walker Health has a sub-award to conduct this research demonstration project funded by the Public Health Service relating to Truvada. The Principal Investigator on the demonstration project, Dr. Richard Elion, has received outside remuneration from Gilead Sciences, Inc., the manufacturer of Truvada. Dr. Elion has made full disclosure of his financial interest in Gilead as required by law and is subject to the terms of a management plan that includes this disclosure statement and oversight mechanisms, including quarterly reviews conducted by WWH’s CEO and CMO, to ensure objectivity in the conduct of the research project.


Below are some academic papers that have been based on research conducted by Whitman-Walker.

Palella, F. J., Gange, S. J., Benning, L., Jacobson, L., Kaplan, R. C., Landay, A. L., et al. (2010). Inflammatory biomarkers and abacavir use in the women's interagency HIV study and the multicenter AIDS cohort study. AIDS, 24(11), 1657-1665.

Ross, L. L., Rouse, E., Gerondelis, P., DeJesus, E., Cohen, C., Horton, J., et al. (2010). Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir. The Journal of Antimicrobial Chemotherapy, 65(2), 307-315.

Baker, J., Plankey, M., Josayma, Y., Elion, R., Chiliade, P., Shahkolahi, A., et al. (2009). The prevalence of rectal, urethral, and pharyngeal neisseria gonorrheae and chlamydia trachomatis among asymptomatic men who have sex with men in a prospective cohort in washington, D.C. AIDS Patient Care and STDs, 23(8), 585-588.

Ross, L., Elion, R., Lanier, R., Dejesus, E., Cohen, C., Redfield, R. R., et al. (2009). Modulation of K65R selection by zidovudine inclusion: Analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). AIDS Research and Human Retroviruses, 25(7), 665-672.

Gathe Jr., J. C., & Elion, R. (2008). Antiretroviral Rounds.  Resistance: What you don't know--can it hurt you? AIDS Clinical Care, 20(6), 51-52.
Financial Conflict of Interest in PHS-Funded Research Policy
Name Owner Date  
Financial Conflict of Interest in PHS-Funded Resea   Chip Lewis 10/7/2013 3:36:40 PM    
List has 1 document on 1 page